Contemporary Hormonal Contraception and the Risk of Breast Cancer. Issue 4 (April 2018)

• Record Type: Journal Article
• Authors: Mørch, Lina S.; Skovlund, Charlotte W.; Hannaford, Philip C.; Iversen, Lisa; Fielding, Shona; Lidegaard, Øjvind
• Is Part Of: Obstetrical & gynecological survey. Volume 73:Issue 4(2018)
• Publication Date: 2018-04
• Subjects: Obstetrics -- Periodicals; Gynecology -- Periodicals; Generative organs, Female -- Surgery -- Periodicals; 618
• DOI: 10.1097/01.ogx.0000531328.30801.b7
• Languages: English
• ISSNs: 0029-7828

Abstract

Abstract : (Abstracted from N Engl J Med 2017;377:2228–2239) It is estimated that worldwide 13% of women between the ages of 15 and 49 years use hormonal contraception. In Denmark, this percentage was 24% in 1995 and increased to 39% by 2012. Use of estrogen promotes the development of breast cancer; the role of progestin is unclear. A large number of studies have reported inconsistent findings of breast cancer risk among women who receive hormonal contraceptives. Whether contemporary hormonal contraception is associated with an increased risk of breast cancer is unknown.